Recurrent visceral leishmaniasis in an immunocompetent patient: a case report by unknown
JOURNAL OF MEDICAL
CASE REPORTS
Lagadinou et al. Journal of Medical Case Reports 2013, 7:68
http://www.jmedicalcasereports.com/content/7/1/68CASE REPORT Open AccessRecurrent visceral leishmaniasis in an
immunocompetent patient: a case report
Maria Lagadinou1, Dimitra Dimitropoulou2, Stelios F Assimakopoulos1*, George Davoulos1 and Markos Marangos2Abstract
Introduction: Current treatment options for visceral leishmaniasis (pentavalent antimony, amphotericin B, liposomal
amphotericin B and mitelfosine) achieve long-term clinical cure in the majority of immunocompetent patients.
Disease relapse is usually provoked by T-cell number or function impairment (corticosteroid or cytotoxic therapy,
transplant recipients, advanced human immunodeficiency virus disease).
Case presentation: We report a case of visceral leishmaniasis with multiple relapses in a 75-year-old Greek
immunocompetent man. Visceral leishmaniasis relapses occurred despite appropriate treatment with liposomal
amphotericin B 3mg/kg/day on days one to five, 14 and 21 (for the first episode and the first relapse) and
mitelfosine 150mg/day for 28 days (for the second relapse). The third relapse was treated with high-dose liposomal
amphotericin B (10mg/kg for two consecutive days), followed by a secondary prophylaxis of 3mg/kg once per
month, which prevented disease reappearance during one year of follow-up.
Conclusion: An unusual case of recurrent visceral leishmaniasis in an older immunocompetent patient was treated
with high-dose liposomal amphotericin B and a monthly prophylaxis with no evidence of a relapse after one year
of follow-up.
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Leishmaniasis is a globally widespread group of parasitic
diseases caused by different species of parasites that be-
long to the genus Leishmania. It is a zoonosis and the
parasite is transmitted by the bite of an infected female
phlebotomine sand fly. Clinically, it is subdivided into vis-
ceral (kala-azar), cutaneous and mucocutaneous forms.
Visceral leishmaniasis (VL), the most severe form, is a dis-
seminated intracellular protozoan infection that targets
tissue macrophages in the liver, spleen and bone marrow.
Leishmania donovani and Leishmania infantum can both
cause VL, but L. infantum is the predominant pathogen in
Mediterranean countries [1,2].
The outcome and clinical features of the disease de-
pend on both parasite properties (infectivity, pathogen-
icity, virulence) and host factors (age, nutritional status,
and efficacy of innate and cell-mediated immunity).
With appropriate treatment, long-term clinical cure is* Correspondence: sassim@upatras.gr
1Department of Internal Medicine, University Hospital of Patras, Rion-Patras
26504, Greece
Full list of author information is available at the end of the article
© 2013 Lagadinou et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumusually achieved; however, eradication of parasites is un-
likely in most patients, as evidenced by the fact that,
despite initial clinical cure, the disease can reactivate
several years later and parasites can be persistently
detected with application of sensitive assay methods like
polymerase chain reaction [3]. Disease relapse occurs
frequently in patients with T-cell number or function im-
pairment (corticosteroid or cytotoxic therapy, transplant
recipients, advanced human immunodeficiency virus dis-
ease). Rarely, spontaneous reactivation can occur in
immunocompetent patients, attributed mainly to drug
resistance or suboptimal treatment regimens [4,5].
Here we report the case of an older immunocompetent
patient who had multiple VL relapses, despite appropriate
treatment with liposomal amphotericin B (L-AmB) and
mitelfosine. His relapsing disease course was attributed to
advanced age-induced immunosuppression as no other
cause was identified.
Case presentation
A 75-year-old Greek man, resident in an urban area,
presented to our hospital complaining of high fever withtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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3kg in one month. His previous medical history was un-
remarkable. A physical examination revealed a moder-
ately enlarged spleen.
Laboratory investigation showed leukopenia (leukocytes:
2100/μL), normochromic-normocytic anemia (hemoglobin:
11.3g/dL) and moderate thrombocytopenia (platelets:
101,000/μL). A high erythrocyte sedimentation rate (ESR)
(90mm/hour) and C-reactive protein (4mg/dL) were also
noticed. The biochemical tests were normal except for ele-
vated serum globulins (4.2g/dL). The serum protein elec-
trophoresis revealed a polyclonal γ-globulin pattern
without detection of a monoclonal component. His chest
X-ray and urine analysis were normal. His blood and urine
culture results were repeatedly negative. A transthoracic
echocardiogram revealed no pathology and his tuberculin
skin test result was negative. An abdominal computed
tomography scan with contrast medium revealed the pres-
ence of a few hyperechogenic splenic lesions. Serology re-
sults for hepatitis A, B, and C, Coxsackie virus, enteric
cytopathic human orphan virus, herpes simplex virus,
Epstein-Barr virus, cytomegalovirus, human immunodefi-
ciency virus, human T-lymphotropic virus type 1 and 2,
toxoplasma, Bartonella henselae, Francisella tularensis,
Coxiella burnetii and Rickettsia conorii were negative.
Wright and rapid plasma reagin tests were also negative.
A full immunological screening with rheumatoid factor,
antinuclear antibodies, antibodies to double-stranded de-
oxyribonucleic acid (DNA), anti-Sm, anti-Ro/SSA, anti-
La/SSB, anti-ribonucleoproteins, anti-Jo-1, anti-Scl-70,
anti-histones, anti-mitochondrial antibodies, anti-smooth
muscle antibodies, centrally accentuated antineutrophil cyto-
plasmic antibodies (c-ANCA), perinuclear antineutrophil
cytoplasmic antibodies (p-ANCA), anti-cardiolipin, and
lupus anticoagulant was negative. A bone marrow as-
piration showed numerous protozoan parasites (Leishmanian
spp.) within macrophages. Serum test results for leish-
mania antibodies and K39 antigen were positive.
After confirming the diagnosis of VL, the patient was
treated with L-AmB 3mg/kg/day on days one to five, 14
and 21 intravenously. His tolerance of amphotericin was
excellent with no significant changes in his kidney and
liver functions. Treatment was completed uneventfully
and was associated with prompt remission of the pa-
tient’s symptoms in conjunction with a gradual recovery
of leukocyte and platelet counts and hematocrit level.
Six months later, he reported intermittent fever and
deterioration of his health. The laboratory tests showed
leukopenia, anemia and thrombocytopenia again. The
physical examination was normal. His blood and urine
cultures were still negative and a new abdominal com-
puted tomographic scan showed no pathological find-
ings. A bone marrow smear revealed the presence of
leishmania amastigotes, though in much lower numbersthan those detected six months previously. The patient
received another complete course of intravenous L-AmB
at the same dose, which resulted in complete clinical
and laboratory remission.
However, three months later, the patient had to be
hospitalized again for a new episode for VL that was
confirmed with a new bone marrow smear. The labora-
tory and serological findings were compatible with the
previous results. A total lymphocyte count and CD4+
percentage, as well as their absolute count, were mea-
sured in order to evaluate the immune status of our pa-
tient. CD4+ cell percentage and absolute count were
found to be relatively low (22% and 450/μm3, respect-
ively). Mitelfosine (ImpavidoW 50mg/Zentaris GmbH,
Germany) was administrated in a dosage of 150mg per
day (three capsules once daily) for 28 days. Treatment
was generally well tolerated; gastrointestinal symptoms
such as vomiting and anorexia were controlled with a
split of the daily dose into two doses, which were co-
administered with food.
Three months later, the patient required another
hospitalization for irregular fever, sweats and fatigue.
The laboratory tests once again revealed pancytopenia.
His test results for leishmania antibodies and K39 anti-
gen were positive. The patient was reluctant to be
subjected to an additional bone marrow biopsy. How-
ever, there was a strong clinical evidence for a new epi-
sode of VL, therefore a new course of L-AmB
administration was decided in a dose of 10mg/kg on
days one to two, in combination with oral mitelfosine.
Unfortunately, the tolerance of mitelfosine was very
poor this time because of vomiting; this led the pa-
tient to stop the drug three days after initiation.
Nevertheless, the administration of high-dose L-Amb
resulted in complete clinicolaboratory response. In
order to prevent further disease relapses, a secondary
prophylaxis with L-AmB once per month at a dose of
3mg/kg was scheduled. Currently, almost a year after
the last VL episode, the patient remains in good
health with normal hematological indices.
Discussion
Leishmania organisms are flagellated protozoa that are
usually transmitted by female phlebotomine sand flies to
mammalian hosts, where they reproduce as obligate
intracellular parasites in the mononuclear phagocytic
system. The cardinal pathogenetic characteristics of
leishmania infection are: (i) the parasite replicates intra-
cellularly in resident tissue macrophages, (ii) the host
immune-inflammatory response regulates the expression
and outcome of the disease and (iii) tissue infection is
usually persistent [6]. Dissemination depends on different
factors such as parasite properties, host factors and host
responses. Ideally, after promastigotes enter macrophages,
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and cell-mediated immunity in order to eradicate the in-
fection, leading to spontaneous healing and prevention of
reactivation. Secretion of proinflammatory Th1-type cyto-
kines such as interferon-γ, interleukin-12 and tumor ne-
crosis factor-α prevents parasitemia and development of
chronic disease. On the contrary, in immunosuppressed
patients, immune responses are ineffective and dissemin-
ation of disease occurs frequently [7].
Current therapies for VL, such as pentavalent antim-
ony, amphotericin B, L-AmB and mitelfosine, lead to
clinical cure in the majority of immunocompetent pa-
tients. Recurrent infections occur within a period of six
months, commonly in patients with impaired cellular
immunity such as individuals with advanced human im-
munodeficiency virus disease or immunosuppressed
transplant recipients [8].
In this article, we report on multiple episodes of relaps-
ing VL in an older patient. Beyond the known decreased
capacity of cytotoxic responses during senescence, no
other immune-suppressing factor was identified in our
case. CD4+ cell percentage and absolute count measured
in the second VL relapse were found to be relatively low
(22% and 450/μm3, respectively). However, even in human
immunodeficiency virus cases with CD4+ cell counts
reaching 250 to 300/μm3 the risk of relapse seems to be
low [9]. To the best of our knowledge, there are very few
reports of relapsing VL in the immunocompetent in the
literature [10].
Initially, our patient was treated with L-Amb and the
same regimen was given in his first episode of relapse.
L-AmB is considered a highly effective regimen for VL
treatment even in immunosuppressed patients [11,12].
However, this treatment option failed to succeed in
chronic suppression of the disease. Mitelfosine, an
alkylphosphocholine with antileishmanial activity, was
used as an alternative treatment in his second episode of
relapse. Studies in immunocompromised patients (hu-
man immunodeficiency virus seropositive) have shown
that the antileishmanial activity of this drug is retained
in this special population, suggesting that mitelfosine
might be a useful option in preventing relapses of the
disease [13]. Unfortunately, even after mitelfosine ther-
apy, our patient had a new episode of VL.
L-AmB shows a concentration-dependent activity
against Leishmania spp, where higher doses of L-AmB
result in a greater reduction of the parasite load and in a
persistence of drug levels in the liver and spleen for a
long period after cessation of therapy [11]. In order to
eradicate the infection, we decided to administer the
high dose and shorter duration scheme of L-AmB
(10mg/kg for two consecutive days) with a subsequent
secondary prophylaxis. Current evidence in acquired im-
mune deficiency syndrome-related VL suggests thatmaintenance treatment with L-AmB at a dose of 3mg/kg
once every three or four weeks may suppress recurrent
infection, probably by inhibition of the reproduction of
the remaining parasites, which represent an endogenous
reservoir responsible for future relapses [14,15]. Our pa-
tient showed an excellent tolerance to therapy with no
renal or electrolyte disturbances and exhibited a complete
clinical and laboratory response.
Conclusions
An unusual case of recurrent VL in an older immuno-
competent patient was effectively treated with high-dose
L-AmB and a monthly prophylaxis with no evidence of
relapse after one year of follow-up. High-dose and
shorter duration regimens of L-AmB seem to be a well-
tolerated therapy in older patients, while maintenance
therapy may be needed in some cases in order to pre-
vent future VL relapses.
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